Abstract
Chronic myeloid leukemia (CML) is a malignant clonal proliferative disease, which originates from multifunctional hematopoietic stem cells of bone marrow. Imatinib is used as the first-line treatment for CML currently, owing to its obvious curative effect for patients in chronic phase and survival time prolonged significantly for patients in accelerated phase and blast crisis. With the long-term application of imatinib in clinic, the drug resistance and intolerance gradually appear, resulting in decreased long-term effects of CML. This paper will review the current status of the pathogenesis and treatment of CML. Key words: Leukemia, myelogenous, chronic; Tyrosine kinase inhibitors; bcr-abl
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
